Hepatic transplant and HCV: A new playground for an old virus

American Journal of Transplantation

Volumn 12, Issue 2, 2012, Pages 298-305

  Chinnadurai, R ^a   Velazquez, V ^a   Grakoui, A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HCV; IFN; immune evasion; innate response; liver; quasispecies; recurrence; T cell; transplantation; viral evolution

Indexed keywords

CD4 ANTIBODY; HLA B27 ANTIGEN; HLA B57 ANTIGEN; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 28; RETINOIC ACID INDUCIBLE PROTEIN I; RNA; TOLL LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ALLOTRANSPLANTATION; CHIMPANZEE; DISEASE COURSE; FIBROSIS; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C VIRUS; HLA SYSTEM; HUMAN; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTIOUS HEPATITIS; INNATE IMMUNITY; KUPFFER CELL; LIVER CELL; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TRANSPLANTATION; MICROENVIRONMENT; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STELLATE CELL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSION; LIVER; LIVER TRANSPLANTATION; RECURRENCE;

EID: 84856433497     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03812.x     Document Type: Review

References (61)

1. Brown RS,. Hepatitis C and liver transplantation. Nature 2005; 436: 973-978.
2. Dustin LB, Rice CM,. Flying under the radar: The immunobiology of hepatitis C. Annu Rev Immunol 2007; 25: 71-99. (Pubitemid 46697903)
3. Major ME, Dahari H, Mihalik K, et al,. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology 2004; 39: 1709-1720. (Pubitemid 38702673)
4. Neumann-Haefelin C, Thimme R,. Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection. Genes Immun 2007; 8: 181-192. (Pubitemid 46672051)
5. Kim AY, Kuntzen T, Timm J, et al,. Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes. Gastroenterology 2011; 140: 686-696.
6. Thomas DL, Thio CL, Martin MP, et al,. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
7. Tanaka Y, Nishida N, Sugiyama M, et al,. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
8. Rehermann B., Hepatitis C virus versus innate and adaptive immune responses: A tale of coevolution and coexistence. J Clin Invest 2009; 119: 1745-1754.
9. Gale M Jr., Foy EM,. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436: 939-945. (Pubitemid 41191669)
10. Cheent K, Khakoo SI,. Natural killer cells and hepatitis C: Action and reaction. Gut 2011; 60: 268-278.
11. Albert ML, Decalf J, Pol S,. Plasmacytoid dendritic cells move down on the list of suspects: In search of the immune pathogenesis of chronic hepatitis C. J Hepatol 2008; 49: 1069-1078.
12. Rodrigue-Gervais IG, Rigsby H, Jouan L, et al,. Dendritic cell inhibition is connected to exhaustion of CD8+ T cell polyfunctionality during chronic hepatitis C virus infection. J Immunol 2010; 184: 3134-3144.
13. Bowen DG, Walker CM,. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 2005; 201: 1709-1714. (Pubitemid 41002889)
14. Fuller MJ, Shoukry NH, Gushima T, et al,. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 2010; 51: 378-387.
15. Pfafferott K, Gaudieri S, Ulsenheimer A, et al,. Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity. PLoS One 2011; 6: e16797.
16. McMahan RH, Golden-Mason L, Nishimura MI, et al,. Tim-3 expression on PD-1 +HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 2010; 120: 4546-4557.
17. von Hahn T, Yoon JC, Alter H, et al,. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007; 132: 667-678. (Pubitemid 46274668)
18. Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC,. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 2009; 136: 2377-2386.
19. Liu L, Fisher BE, Dowd KA, Astemborski J, Cox AL, Ray SC,. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol 2010; 84: 5067-5077.
20. Thomson AW, Knolle PA,. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 2010; 10: 753-766.
21. Sumpter TL, Abe M, Tokita D, Thomson AW,. Dendritic cells, the liver, and transplantation. Hepatology 2007; 46: 2021-2031.
22. Schurich A, Berg M, Stabenow D, et al,. Dynamic regulation of CD8 T cell tolerance induction by liver sinusoidal endothelial cells. J Immunol 2010; 184: 4107-4114.
23. Chinnadurai R, Grakoui A,. B7-H4 mediates inhibition of T cell responses by activated murine hepatic stellate cells. Hepatology 2010; 52: 2177-2185.
24. Holz LE, Benseler V, Bowen DG, et al,. Intrahepatic murine CD8 T-cell activation associates with a distinct phenotype leading to Bim-dependent death. Gastroenterology 2008; 135: 989-997.
25. Wuensch SA, Spahn J, Crispe IN,. Direct, help-independent priming of CD8+ T cells by adeno-associated virus-transduced hepatocytes. Hepatology 2010; 52: 1068-1077.
26. Watt K, Veldt B, Charlton M,. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant 2009; 9: 1707-1713.
27. Carrion JA, Navasa M, Forns X,. Retransplantation in patients with hepatitis C recurrence after liver transplantation. J Hepatol 2010; 53: 962-970.
28. Dragun J, Perez-Del-Pulgar S, Crespo G, et al,. Characterization of the cross-neutralizing antibody response against hepatitis C virus in the liver transplantation setting. Am J Transplant 2011; 11: 767-774.
29. Garcia-Retortillo M, Forns X, Feliu A, et al,. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-687. (Pubitemid 34183974)
30. Charlton M., Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 2003; 9: S58-S62. (Pubitemid 37408005)
31. Ciccorossi P, Maina AM, Oliveri F, et al,. Viral load 1 week after liver transplantation, donor age and rejections correlate with the outcome of recurrent hepatitis C. Liver Int 2007; 27: 612-619. (Pubitemid 47097310)
32. Shackel NA, Jamias J, Rahman W, et al,. Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl 2009; 15: 709-718.
33. Carrion JA, Torres F, Crespo G, et al,. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010; 51: 23-34.
34. Zimmermann T, Otto C, Hoppe-Lotichius M, et al,. Risk factors in patients with rapid recurrent hepatitis C virus-related cirrhosis within 1 year after liver transplantation. Transplant Proc 2009; 41: 2549-2556.
35. Lopez-Labrador FX, Bracho MA, Berenguer M, et al,. Genetic similarity of hepatitis C virus and fibrosis progression in chronic and recurrent infection after liver transplantation. J Viral Hepat 2006; 13: 104-115.
36. Ramirez S, Perez-del-Pulgar S, Carrion JA, et al,. Hepatitis C virus superinfection of liver grafts: A detailed analysis of early exclusion of non-dominant virus strains. J Gen Virol 2010; 91: 1183-1188.
37. Schvoerer E, Soulier E, Royer C, et al,. Early evolution of hepatitis C virus (HCV) quasispecies after liver transplant for HCV-related disease. J Infect Dis 2007; 196: 528-536. (Pubitemid 47206098)
38. Ramirez S, Perez-Del-Pulgar S, Carrion JA, et al,. Hepatitis C virus compartmentalization and infection recurrence after liver transplantation. Am J Transplant 2009; 9: 1591-1601.
39. Fafi-Kremer S, Fofana I, Soulier E, et al,. Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med 2010; 207: 2019-2031.
40. González-Candelas F, Lõpez-Labrador FX,. Clinical relevance of genetic heterogeneity in HCV. Future Virology 2010; 5: 33-49.
41. Mensa L, Crespo G, Gastinger MJ, et al,. Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology 2011; 53: 1436-1445.
42. Gane EJ, Naoumov NV, Qian KP, et al,. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-177. (Pubitemid 26021616)
43. Grakoui A, Shoukry NH, Woollard DJ, et al,. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302: 659-662. (Pubitemid 37310924)
44. Shoukry NH, Grakoui A, Houghton M, et al,. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197: 1645-1655. (Pubitemid 36745340)
45. Lee YR, Yang IH, Lee YH, et al,. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 2005; 105: 3951-3955.
46. Izopet J, Rostaing L, Sandres K, et al,. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis 2000; 181: 852-858. (Pubitemid 30194465)
47. Rosen HR, Marousek G, Chou S,. A longitudinal analysis of T-cell epitope-coding regions of hepatitis C virus after liver transplantation. Transplantation 2002; 74: 209-216. (Pubitemid 34810288)
48. Mello IM, Thumann C, Schvoerer E, et al,. Conservation of hepatitis C virus nonstructural protein 3 amino acid sequence in viral isolates during liver transplantation. J Viral Hepat 2009; 16: 732-737.
49. Sanchez-Fueyo A, Gimenez-Barcons M, Puig-Basagoiti F, et al,. Influence of the dynamics of the hypervariable region 1 of hepatitis C virus (HCV) on the histological severity of HCV recurrence after liver transplantation. J Med Virol 2001; 65: 266-275.
50. Massaguer A, Ramirez S, Carrion JA, Gonzalez P, Sanchez-Tapias JM, Forns X,. Evolution of the NS3 and NS5B regions of the hepatitis C virus during disease recurrence after liver transplantation. Am J Transplant 2007; 7: 2172-2179. (Pubitemid 47247041)
51. Wang GP, Sherrill-Mix SA, Chang KM, Quince C, Bushman FD,. Hepatitis C virus transmission bottlenecks analyzed by deep sequencing. J Virol 2010; 84: 6218-6228.
52. Li H, Sullivan DG, Feuerborn N, et al,. Genetic diversity of hepatitis C virus predicts recurrent disease after liver transplantation. Virology 2010; 402: 248-255.
53. Selzner N, Guindi M, Renner EL, Berenguer M,. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55: 207-217.
54. Pan Q, Metselaar HJ, de Ruiter P, et al,. Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha. Liver Transpl 2010; 16: 520-526.
55. Fukuhara T, Taketomi A, Motomura T, et al,. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585.
56. Motomura T, Taketomi A, Fukuhara T, et al,. The impact of IL28B genetic variants on recurrent hepatitis C in liver transplantation: Significant lessons from a dual graft case. Am J Transplant 2011; 11: 1325-1329.
57. Nellore A, Fishman JA,. NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis 2011; 52: 369-377.
58. Rosen HR, Doherty DG, Madrigal-Estebas L, O'Farrelly C, Golden-Mason L,. Pretransplantation CD56(+) innate lymphocyte populations associated with severity of hepatitis C virus recurrence. Liver Transpl 2008; 14: 31-40. (Pubitemid 351167986)
59. Ohira M, Ishiyama K, Tanaka Y, et al,. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest 2009; 119: 3226-3235.
60. Weston SJ, Leistikow RL, Reddy KR, et al,. Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantation. Hepatology 2005; 41: 72-81. (Pubitemid 40068845)
61. Hashimoto K, Miller C, Hirose K, et al,. Measurement of CD4+ T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. Clin Transplant 2010; 24: 701-708.